Am I eligible for the free bowel cancer screening test in Australia?

If you are aged between 45 and 74 and an Australian citizen or permanent resident, you are eligible to receive a free bowel cancer screening kit in the mail every two years. If you have not received a kit, or have a personal or family history of bowel cancer or polyps, speak with your GP about your individual screening needs.

What happens if the home screening test comes back positive?

A positive iFOBT result does not mean you have cancer — it means blood was detected in your stool, which requires further investigation. Your GP will generally arrange a colonoscopy to determine the cause. The majority of positive screening results do not turn out to be cancer, but all positive results warrant follow-up.

Bowel cancer screening: why the national June campaign matters at 45

What just happened

On 1 June 2026, the Australian Government’s National Bowel Cancer Screening Program launched a major new national campaign with a single, unambiguous headline: Bowel cancer waits for no one. The campaign is a direct response to a number that has not moved enough in years — only 41.7% of eligible Australians aged 45 to 74 complete their free home test. If that number reached 60%, researchers estimate 84,000 lives could be saved in Australia by 2040.

That gap is not about access. The National Bowel Cancer Screening Program mails an immunochemical faecal occult blood test (iFOBT) directly to your door, free, every two years. No GP visit required, no appointment, no fasting. The kit is designed to be completed at home in a few minutes. And yet, almost six in ten eligible Australians are not doing it.

If you are 45 or older, this campaign is partly addressed to you. The program’s lower age bound was extended in 2024 from 50 to 45 — a change based on evidence that colorectal cancer rates in people aged 45 to 49 have been rising in Australia and in comparable countries over recent decades. The 45-year-old woman who has been navigating perimenopause and a stretched general practice system is now squarely in scope.

The reason this matters for midlife women specifically: bowel cancer symptoms — irregular bowel habits, rectal bleeding, abdominal discomfort, unexplained fatigue, weight change — overlap substantially with other conditions in this cohort, including irritable bowel syndrome, endometriosis, and the hormonal shifts of perimenopause. AIHW data confirms bowel cancer is the second most commonly diagnosed cancer in Australia, and critically, one of the most survivable when caught at an early stage. Stage I bowel cancer has a five-year survival rate over 90%. Stage IV is below 15%.

The both-and

Bowel cancer screening works. Most eligible Australians are still not doing it. Neither fact cancels the other, and they need to be held together to understand why this campaign exists.

The evidence base is solid and mature

The iFOBT used in Australia’s national program has been evaluated in large randomised controlled trials spanning decades across multiple countries. It detects haemoglobin from blood in the stool, which can be shed by polyps or early cancers before symptoms appear. A positive result does not diagnose cancer — it triggers further investigation, generally colonoscopy. The program is specifically designed to catch precancerous adenomatous polyps and early-stage cancers, both of which are highly amenable to treatment.

The 2024 extension to 45-year-olds reflects a genuine epidemiological shift. Younger adults are now being diagnosed with colorectal cancer at higher rates than previous generations, and the program was adjusted to reflect that change rather than waiting for the evidence to become overwhelming.

The low-uptake problem is not about access — it is about the body, friction, and avoidance

Research consistently identifies several reasons screening rates stall despite free, home-delivered kits: discomfort with the mechanics of a stool-based test, squeamishness, avoidance of confronting a possible adverse result, and — across culturally and linguistically diverse communities — additional barriers around body norms and language access. The new campaign’s multicultural component (Arabic, Mandarin, and Vietnamese in-language materials) and community roadshows targeting Aboriginal and Torres Strait Islander communities are direct responses to documented disparities in uptake.

There is also the structural problem specific to midlife women. When a 45-year-old is already managing a full general practice waiting list, persistent fatigue, a thyroid follow-up, perimenopause symptoms, and a household that runs on her bandwidth, a screening kit on the kitchen bench can stay there for weeks. That is not indifference. It is overload. Acknowledging this is not an excuse for inaction — but the campaign’s community-roadshow and activations model suggests its designers know that awareness alone does not move the needle.

The colonoscopy bottleneck is real and undiscussed

A positive screening result leads to colonoscopy, and colonoscopy access in Australia has well-documented wait-time disparities — particularly outside major urban centres. Raising screening uptake without simultaneously expanding downstream capacity means that a higher positive-test rate will meet a constrained supply of gastroenterology services. This is not raised as a reason to avoid screening. It is worth naming as the system problem that trails the campaign’s success metric.

2 cents

If you have not received an NBCSP kit yet, or received one and set it aside: this is a reasonable week to complete it. The test takes approximately ten minutes at home and does not require a GP visit to access — the program posts it to you. If you have turned 45 this year or last year, you are now eligible and a kit should arrive automatically.

If you have a personal or family history of bowel cancer, colorectal polyps, or a hereditary condition like Lynch syndrome or familial adenomatous polyposis, the standard 2-yearly iFOBT is unlikely to be the right interval for your situation. That warrants a specific conversation with your GP about surveillance colonoscopy scheduling — separate from the population program.

If you received a positive result on a recent kit and have been deferring the colonoscopy: the gap between a positive screen and colonoscopy follow-through is where people are most likely to slip through. That deferral is worth addressing.

This is general health information about a national screening program. Individual screening needs depend on personal and family history. Speak with your GP about what is right for your situation.

Verdict

Verdict: yes — worth knowing about.

The bowel cancer screening campaign is not scientific news — it is a well-evidenced public health program that most eligible Australians are still not using. For the woman this site exists for: you are now in the program’s age range, the test is free and mailed to you, and the June 2026 campaign is a reasonable prompt to act on a kit that may have been sitting on the bench.